zilovertamab vedotin

Zilovertamab vedotin is an investigational antibody-drug conjugate (ADC) designed to selectively target the receptor tyrosine kinase-like orphan receptor 1 (ROR1), a transmembrane protein overexpressed in various hematologic malignancies and some solid tumors. The drug consists of a humanized IgG1 monoclonal antibody directed against ROR1, linked via a proteolytically cleavable linker to the cytotoxic agent monomethyl auristatin E (MMAE). Upon binding to ROR1-expressing cells, the ADC is internalized, and MMAE is released intracellularly, where it inhibits tubulin polymerization, leading to cell cycle arrest and apoptosis. Zilovertamab vedotin has demonstrated promising antitumor activity in preclinical models and early-phase clinical trials for several cancers. It is being developed primarily by Merck and was originally discovered by VelosBio[2][3][4][5][7].

Other names

UC-961 antibody-drug conjugateUC961 antibody-drug conjugateUC 961 antibody-drug conjugate